The behaviour of various platelet function tests during long-term prostacyclin infusion in patients with peripheral vascular disease.
In 20 patients with peripheral vascular disease treated with prostacyclin (5 ng/kg/min) we observed a significant activation of platelet function as measured by platelet proteins, ADP-induced aggregation platelet sensitivity and platelet count. Only the platelet survival was significantly prolonged by the treatment.
D000328:Adult; D000368:Aged; D002470:Cell Survival; D011464:Epoprostenol / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation; D010976:Platelet Count; D010978:Platelet Factor 4 / Q000032:analysis; D010979:Platelet Function Tests; D013997:Time Factors; D014652:Vascular Diseases / Q000097:blood / Q000188:drug therapy*; D001620:beta-Thromboglobulin / Q000032:analysis
D001620:beta-Thromboglobulin; D010978:Platelet Factor 4; D011464:Epoprostenol